RGTL.F Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.23 |
| 52 Week High | AU$2.20 |
| 52 Week Low | AU$0.14 |
| Beta | 1.05 |
| 11 Month Change | 15.03% |
| 3 Month Change | n/a |
| 1 Year Change | -89.05% |
| 33 Year Change | -99.49% |
| 5 Year Change | -99.30% |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGTL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -59.5% | -0.1% | 2.6% |
| 1Y | -89.0% | 21.2% | 30.5% |
Return vs Industry: RGTL.F underperformed the US Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: RGTL.F underperformed the US Market which returned 30.5% over the past year.
Price Volatility
| RGTL.F volatility | |
|---|---|
| RGTL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGTL.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RGTL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| RGTL.F fundamental statistics | |
|---|---|
| Market cap | US$10.55m |
| Earnings (TTM) | -US$11.93m |
| Revenue (TTM) | US$606.63k |
17.4x
P/S Ratio-0.9x
P/E RatioIs RGTL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGTL.F income statement (TTM) | |
|---|---|
| Revenue | AU$891.08k |
| Cost of Revenue | AU$1.20m |
| Gross Profit | -AU$304.15k |
| Other Expenses | AU$17.23m |
| Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -34.13% |
| Net Profit Margin | -1,967.34% |
| Debt/Equity Ratio | -149.0% |
How did RGTL.F perform over the long term?
See historical performance and comparison